FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Juva Life Inc. (the “Issuer”).

Trading Symbol: JUVA

Number of Outstanding Listed Securities: 164,016,223

Date: January 2, 2023

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The principal business of the Issuer is to, own, and operate various cannabis businesses in the state of California. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs.**

**The Issuer operates in the medical and recreational cannabis sectors in California, USA. While some states in the United States have authorized the use and sale of marijuana, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against marijuana is subject to change. Because the Company will be engaging in the marijuana-related activities in the US, it assumes certain risks due to conflicting state and federal laws. The federal law relating to marijuana could be enforced at any time and this would put the Company at risk of being prosecuted and having its assets seized when the Company starts operations in the cannabis sector.**

**On August 18, 2021, the Issuer announced initial pre-clinical discovery results from the phenotypic screening and target profiling of its proprietary cannabis chemical library. The initial results of this effort have identified Juva-019 which has been nominated for development.**

**Juva-019 is a non-cannabinoid purified small molecule isolated from Cannabis with broad spectrum anti-inflammatory properties. Juva-019 is potent modulator of TNF-alpha, IL-1 beta, and several other clinically relevant cytokines. Juva-019 acts at known targets implicated in inflammation and diseases of aging.**

**While most of the research and development into Cannabis has focused on the cannabinoids, the Issuer believes that other chemical components may also explain the observed therapeutic benefits of Cannabis. The Issuer has developed a proprietary chemical library of natural and semi-synthetic non-cannabinoids and is systematically evaluating their therapeutic benefit alone and in combination across panels of industry-standard phenotypic and target-based anti-inflammatory assays. The result of this initial effort is a pipeline of proprietary bioactives amenable to consumer and pharmaceutical product development, discovered at a fraction of the cost, time and risk of traditional drug development efforts.**

**The Issuer’s focus for the next six months is to build its discovery pipeline and initiate lead-optimization on the first series of individual compounds identified. The Issuer is executing a dual naturals and semi-synthetic optimization and commercialization approach. The Company will seek to commercialize with consumer products companies the natural chemical motif alone or in rationally designed combinations through a consumer products/OTC pathway, and in parallel apply traditional medicinal chemistry tools to optimize and select compounds to achieve drug-like effects. The Issuer may seek to enter pharmaceutical company partnerships to develop its semi-synthetic and synthetic analogs.**

1. Provide a general overview and discussion of the activities of management.

**The Issuer is made up of six divisions: Cultivation, Research, Manufacturing, Distribution, Retail and Delivery. Each division services specific vertical markets within a fully integrated framework under the guiding premise of commercially engaging the many ways cannabis can fundamentally improve individual quality of life.**

**The Issuer’s strategic plan is to be a fully autonomous, vertically-integrated cannabis business with two primary missions: (1) to achieve the lowest cost of production by owning licenses for retail sales, manufacturing, distribution and cultivation of cannabis and to employ each license to propel our supply chain with select brick and mortar storefronts and multiple delivery businesses throughout the State of California; and (2) to develop "precision cannabis" products that deliver the right formulation to the right individual at the right time. Juva plans to develop intellectual property and secure patent protection on each of its custom medical formulations and will focus its research registries in areas of inflammation, oncology, neurology, pain management and opiate reduction.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None noted.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None noted.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None noted.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None noted.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None noted.**

1. Describe the acquisition of new customers or loss of customers.

**None noted.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None noted.**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None noted.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**None noted.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None noted.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None noted.**

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds** |
| **N/A** |  |  |  |
|  |  |  |  |

1. Provide details of any loans to or by Related Persons.

**None noted.**

1. Provide details of any changes in directors, officers or committee members.

**None noted.**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Legalization of cannabis for recreational use in Canada and the growing number of states in the United States allowing cannabis for medical and/or recreational use, the potential market for cannabis products is only expected to grow. However, the market and regulatory framework within which the Issuer operates continues to evolve and remains subject to change and there are no assurances that such market and framework will develop in a manner consistent with the Issuer’s current expectations or at all.**

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 2, 2023.

 Mathew Lee
Name of Director or Senior Officer

 *“Mathew Lee”*
Signature

 Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerJuva Life Inc. | For Month EndDecember 2022 | Date of ReportYY/MM/D23/01/02 |
| Issuer AddressSuite 1400 – 885 West Georgia Street |
| City/Province/Postal CodeVancouver, BC V6C 3E8 | Issuer Fax No.n/a | Issuer Telephone No.(833) 333-5882 |
| Contact NameMathew Lee | Contact PositionChief Financial Officer | Contact Telephone No.(833) 333-5882 |
| Contact Email Addressmat@juvalife.com | Web Site Address[www.juvalife.com](http://www.juvalife.com) |